Skip to search formSkip to main contentSkip to account menu

PARP-1/2 Inhibitor ABT-767

Known as: ABT-767 
An orally available inhibitor of the nuclear enzymes poly(ADP-ribose) polymerase (PARP) 1 and 2, with potential antineoplastic activity. Upon… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Citation for published version (APA): van der Biessen, D. A. J., Gietema, J. A., de Jonge, M. J. A., Desar, I. M. E., den… 
2017
2017
SummaryPurpose This phase 1 study examined safety, pharmacokinetics (PK), and efficacy of the poly(ADP-ribose) polymerase (PARP… 
2017
2017
PurposeThe objective of the manuscript is to describe the development of a population pharmacokinetic model for ABT-767, a potent… 
2015
2015
BACKGROUND: Malignancies with homologous repair deficiency (HRD) are more dependent on PARP for DNA repair than normal cells… 
2014
2014
ABSTRACT Background: ABT-767 is a potent oral inhibitor of PARP-1 and -2. Malignancies with defects in homologous repair are more…